US OptionsDetailed Quotes
VKTX240816C58000
- 0.03
- -0.37-92.50%
15min DelayClose Aug 16 16:00 ET
0.62High0.03Low
0.19Open0.40Pre Close167 Volume1.10K Open Interest58.00Strike Price2.01KTurnover231.99%IV2.33%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type0.0760Delta0.1614Gamma1890.33Leverage Ratio-3.7168Theta0.0000Rho143.59Eff Leverage0.0005Vega
Viking Therapeutics Stock Discussion
Sign in to post a comment
$Eli Lilly and Co (LLY.US)$ reports earnings before markets open on August 8, with analysts projecting revenue and profits to be boosted by the popularity of the weight-loss drugs Mounjaro and Zepbound.
Eli Lilly shares have risen by more than 38% since the start of the year, closing at $804.46 last Friday, but down from the record level of $996.1 seen earlier this month.
The drugmaker is projected to report $9.99 billion in revenue, a 20% bump ...
Eli Lilly shares have risen by more than 38% since the start of the year, closing at $804.46 last Friday, but down from the record level of $996.1 seen earlier this month.
The drugmaker is projected to report $9.99 billion in revenue, a 20% bump ...
24
1
Unsupported module.
Please view on mobile devices.
7
$Viking Therapeutics (VKTX.US)$ could have bought this for 20b, what losers
Shares of Viking Therapeutics soared nearly 40% intraday following discussions with the FDA that accelerated the development of their weight loss candidate VK2735 to phase 3 trials, potentially advancing its market debut by a year. This drug, administered monthly, is anticipated to be more convenient than Eli Lilly and Novo Nordisk's treatments. The oral version of VK2735 will be...
1
$Viking Therapeutics (VKTX.US)$
What drove stock move?
⇨ VK2735 oral 💊
» Oral dosing up to 80 mg looks tolerable enough to go to 100 mg
» No more catalyst drought with Obesity Week oral VK2735 readout added in Q4 (see 📸 for updated 2024 readouts)
» Should be an exciting Obesity Week 2024
⇨ VK2735 subq 💉
» Can go right to Ph3 based on FDA feedback - no Ph2b needed
» Testing monthly subq VK2735 based on PK data
⇨ VK2809 in NASH
» Still looking to partner Ph3/MACE
⇨ V...
What drove stock move?
⇨ VK2735 oral 💊
» Oral dosing up to 80 mg looks tolerable enough to go to 100 mg
» No more catalyst drought with Obesity Week oral VK2735 readout added in Q4 (see 📸 for updated 2024 readouts)
» Should be an exciting Obesity Week 2024
⇨ VK2735 subq 💉
» Can go right to Ph3 based on FDA feedback - no Ph2b needed
» Testing monthly subq VK2735 based on PK data
⇨ VK2809 in NASH
» Still looking to partner Ph3/MACE
⇨ V...
6
$Viking Therapeutics (VKTX.US)$ Gonna tap on 61.2.
1
1
No comment yet
105535782 : ok